ACADIA Pharmaceuticals Inc. (ACAD)
ACADIA Pharmaceuticals Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in San Diego, CA, US. The stock last traded at $29.71, up 1.04% on the session, giving a market capitalisation of $5.09B. On trailing twelve-month figures it carries a trailing P/E of 13.21, a net margin of 33.4%. Its beta of 0.84 implies it has historically moved less than the broad market.
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
ACADIA Pharmaceuticals Inc. is most often compared with the following Healthcare names: